When extended-release methylphenidate underperforms: three children with ADHD and gastrointestinal disease

Methylphenidate (MPH) is the first-line pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD) in children, available in immediate-release (IR) and extended-release (ER) formulations with distinct release profiles. Whether gastrointestinal pathology might selectively affect one or the other has received little clinical attention. We here report three patients with ADHD followed in a single paediatric centre, each with a gastrointestinal disease affecting either absorption…

via https://pubmed.ncbi.nlm.nih.gov/43033244/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1HYeX0emtvYgH07Wkz0a8n9otrdMd-JIklc_uo0I5vh1u9WMEy&fc=None&ff=20261116041620&v=2.20.1


Post a Comment

Your email is never published nor shared. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>